EQT Corporation (EQT)
EQT Corporation (EQT) is a Great Momentum Stock: Should You Buy?
Does EQT Corporation (EQT) have what it takes to be a top stock pick for momentum investors? Let's find out.
EQT (EQT) Upgraded to Strong Buy: Here's Why
EQT (EQT) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
This Top Oils and Energy Stock is a #1 (Strong Buy): Why It Should Be on Your Radar
The Zacks Rank offers investors a way to easily find top-rated stocks and build a winning investment portfolio. Here's why you should take advantage.
EQT (EQT) Up 8.3% Since Last Earnings Report: Can It Continue?
EQT (EQT) reported earnings 30 days ago. What's next for the stock?
Here's Why EQT Corporation (EQT) is a Strong Momentum Stock
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
3 Under-the-Radar GARP Stocks That Could Beat Big Tech
With mega-cap tech names dominating many equities conversations in recent quarters, investors might be seeking an alternative with a bit more breadth. So-called GARP stocks—named because of their potential to provide "growth at a reasonable price"—aim to combine elements of value and growth names in a single investment.
EQT Stock Gains 31% in a Year: Here's What Investors Should Know
EQT shares rise 31% in a year as rising natural gas demand, stronger prices and robust free cash flow boost the outlook, though higher costs and price volatility pose risks.
Why EQT Corporation (EQT) is a Top Momentum Stock for the Long-Term
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Why EQT Corporation (EQT) is a Top Value Stock for the Long-Term
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
EQT backs out of takeover bid for UK's Oxford Biomedica
Private equity group EQT said on Wednesday it had decided not to proceed with a takeover offer for Oxford Biomedica , sending the British cell and gene therapy manufacturer's shares down nearly 10%.
EQT Q4 Earnings Top Estimates on Higher Realized Gas-Equivalent Prices
EQT beats Q4 earnings and revenue estimates as higher realized natural gas prices and stronger sales volumes drive growth.
